Repository logo
 
Publication

Speech and voice response to a Levodopa challenge in late-stage Parkinson’s disease

2017-08-22Journal article Open access
Simple item page
dc.contributor.authorFabbri, Margherita
dc.contributor.authorGuimarães, Isabel
dc.contributor.authorCardoso, Rita
dc.contributor.authorCoelho, Miguel
dc.contributor.authorGuedes, Leonor Correia
dc.contributor.authorRosa, Mário M
dc.contributor.authorGodinho, Catarina
dc.contributor.authorAbreu, Daisy
dc.contributor.authorGonçalves, Nilza
dc.contributor.authorAntonini, Angelo
dc.contributor.authorFerreira, Joaquim
dc.date.accessioned2022-03-31T17:10:51Z
dc.date.available2022-03-31T17:10:51Z
dc.date.issued2017-08-22
dc.description.abstractBackground: Parkinson’s disease (PD) patients are affected by hypokinetic dysarthria, characterized by hypophonia and dysprosody, which worsens with disease progression. Levodopa’s (l-dopa) effect on quality of speech is inconclusive; no data are currently available for late-stage PD (LSPD). Objective: To assess the modifications of speech and voice in LSPD following an acute l-dopa challenge. Method: LSPD patients [Schwab and England score <50/Hoehn and Yahr stage >3 (MED ON)] performed several vocal tasks before and after an acute l-dopa challenge. The following was assessed: respiratory support for speech, voice quality, stability and variability, speech rate, and motor performance (MDS-UPDRS-III). All voice samples were recorded and analyzed by a speech and language therapist blinded to patients’ therapeutic condition using Praat 5.1 software. results: 24/27 (14 men) LSPD patients succeeded in performing voice tasks. Median age and disease duration of patients were 79 [IQR: 71.5–81.7] and 14.5 [IQR: 11–15.7] years, respectively. In MED OFF, respiratory breath support and pitch break time of LSPD patients were worse than the normative values of non-parkinsonian. A correlation was found between disease duration and voice quality (R = 0.51; p = 0.013) and speech rate (R = −0.55; p = 0.008). l-Dopa significantly improved MDS-UPDRS-III score (20%), with no effect on speech as assessed by clinical rating scales and automated analysis. conclusion: Speech is severely affected in LSPD. Although l-dopa had some effect on motor performance, including axial signs, speech and voice did not improve. The applicability and efficacy of non-pharmacological treatment for speech impairment should be considered for speech disorder management in PD.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doihttps://doi.org/10.3389/fneur.2017.00432pt_PT
dc.identifier.issn1664-2295
dc.identifier.urihttp://hdl.handle.net/10400.26/39985
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.subjectParkinson’s diseasept_PT
dc.subjectLate stagept_PT
dc.subjectLevodopapt_PT
dc.subjectSpeechpt_PT
dc.subjectVoicept_PT
dc.titleSpeech and voice response to a Levodopa challenge in late-stage Parkinson’s diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage7pt_PT
oaire.citation.issue2017pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleFrontiers in Neurologypt_PT
person.familyNameGuimarães
person.familyNamecardoso
person.givenNameIsabel
person.givenNamerita
person.identifier548796
person.identifier.ciencia-idF014-BFD6-49C2
person.identifier.orcid0000-0001-8524-8731
person.identifier.orcid0000-0002-4478-990X
person.identifier.scopus-author-id24586862700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationdc9a77a2-eecf-4d30-88fa-4200275eccf5
relation.isAuthorOfPublication0d976fcb-d1b8-478a-8163-250052500b7f
relation.isAuthorOfPublication.latestForDiscovery0d976fcb-d1b8-478a-8163-250052500b7f

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fneur-08-00432.pdf
Size:
147.32 KB
Format:
Adobe Portable Document Format
Download

Collections

ESSA - TF - Artigos em revistas científicas